Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required) | RFA DA 25 057

Opportunity Information: Apply for RFA DA 25 057

The NIH funding opportunity RFA-DA-25-057 supports the development and testing of treatment algorithms for Stimulant Use Disorder (StUD) that combine neuromodulation with behavioral interventions, with a specific emphasis on enrolling or enriching the study sample for a high-risk "vulnerable phenotype." The core problem the announcement targets is that, unlike several other psychiatric conditions, StUD still has no FDA-approved medications, and treatment development has been slowed by the fact that people with StUD are not a uniform group. The initiative is built around the idea that the field may make faster progress by focusing on a subgroup with particularly high clinical need and clearer mechanistic targets, especially individuals characterized by low executive functioning and impaired response regulation, often described in the notice as an anxious-impulsive profile. In practical terms, the opportunity is asking teams to move beyond one-size-fits-all approaches and to rigorously evaluate combined, multi-component interventions that are tailored to this vulnerability pattern.

On the neuromodulation side, the notice highlights approaches such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) as examples of technologies that could be leveraged for StUD. TMS is presented as a clinically validated neuromodulation modality with an established track record in major depressive disorder and, more recently, obsessive-compulsive disorder, which helps justify why it might be a plausible tool for addressing addiction-related neurocircuit dysfunction. tDCS is described as an actively developing approach across mental and neurological disorders and is noted as potentially relevant to the cognitive dysfunction, compulsivity, and impulsivity that can be prominent in the vulnerable StUD phenotype. The announcement also leaves room for other neuromodulation technologies, signaling openness to innovative or emerging tools as long as the scientific rationale and the clinical testing plan are strong.

A central requirement of the opportunity is that the work be carried out through randomized controlled trials. The goal is not simply to show that a single intervention can help, but to develop and compare treatment algorithms, meaning structured decision pathways that specify how neuromodulation and behavioral components are combined, timed, sequenced, or adapted to patient response. The behavioral components explicitly mentioned include cognitive behavioral therapy (CBT) and mindfulness-based approaches, with the broader aim of helping people sustain reductions in stimulant use and prevent relapse. The emphasis on combination treatment reflects a practical clinical reality: even if neuromodulation can reduce cravings or improve executive control, durable recovery often depends on skills-based or behavior-change supports that help individuals manage triggers, regulate emotion, and maintain engagement over time.

Mechanistically, the opportunity is rooted in the observation that not everyone who uses stimulants develops addiction, and that vulnerability is shaped by measurable traits and functional impairments. By focusing on individuals with deficits in executive function and response inhibition, the initiative aligns the treatment-development strategy with neurobiological targets that neuromodulation may plausibly influence, such as prefrontal control systems involved in self-regulation and decision-making. In other words, the notice is encouraging applicants to connect the clinical phenotype (anxious-impulsive traits, poor cognitive control) to an intervention approach (neuromodulation plus behavioral therapy) and then to test that approach in a rigorous trial framework designed to identify the most effective algorithm.

The funding mechanism is a U01 cooperative agreement, which typically indicates substantial involvement from the funding agency during the project, often through collaborative oversight, milestone tracking, and coordination intended to keep complex clinical research on track. The opportunity falls under the Education and Health activity category and is associated with CFDA number 93.279. The original closing date listed is 2024-11-27, and the stated award ceiling is $500,000. While the notice text provided does not specify the exact number of expected awards, the emphasis on algorithm development through randomized trials suggests the agency is looking for well-developed, trial-ready proposals with clear operational plans, recruitment strategies for the vulnerable phenotype, and concrete methods for comparing combined-treatment approaches.

Eligibility is broad and includes many types of domestic applicants, such as state, county, and local governments; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations; public housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The opportunity also explicitly calls out additional eligible applicant categories that reflect an interest in inclusive participation and capacity building across diverse settings, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, regional organizations, non-U.S. entities (foreign organizations), and U.S. territories or possessions. Taken together, the eligibility language suggests the agency is open to applications from both research-intensive centers and community-linked institutions, which can be important for recruiting and retaining populations most affected by stimulant-related harms.

Overall, this grant opportunity is aimed at accelerating clinically actionable, evidence-based treatment development for StUD by testing combined neuromodulation and behavioral interventions in randomized controlled trials, with a strategic focus on a high-need, mechanistically relevant vulnerable phenotype. The intended output is not just another isolated efficacy result, but a practical and empirically supported algorithm that clinicians and treatment systems could use to reduce stimulant use and lower relapse risk in the subgroup most likely to struggle with self-regulation and executive control.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2024-06-27.
• Applicants must submit their applications by 2024-11-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 25 057

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: